CAS · 183133-96-2
Product Overview
Cabazitaxel is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | White or almost white crystalline powder |
|---|---|
| Purity (HPLC) | 99% min |
| Specific rotation | -39.0 ~ -45.0° |
| Loss on drying | 1% max |
| Water | 1% max |
| Identification (HPLC) | The retention time of the major peak in the chromatogram of the assay preparation corresponds to that in the chromatogram of the standard, as obtained in the assay |
| Identification (IR) | The IR spectrum of sample corresponds to that of reference standard |
| Related substance - Any unknown single impurity | 0.2% max |
| Related substance - Total impurities | 1% max |
| Residual Solvents - Ethanol | 0.5% max |
| Residual Solvents - Methanol | 0.3% max |
| Residual Solvents - Dichloromethane | 0.06% max |
| Residual Solvents - N-Hexane | 0.029% max |
| Residual Solvents - Acetic Ether | 0.5% max |
| Residual Solvents - Acetone | 0.5% max |
| Residual Solvents - THF | 0.072% max |
| Residual Solvents - Heptane | 0.5% max |
| Residue on ignition | 0.2% max |
| Heavy metals | 20 ppm max |
Applications
Cabazitaxel is primarily used in oncology as a chemotherapeutic agent for treating metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously undergone treatment with docetaxel. It is administered intravenously in combination with prednisone or prednisolone. Cabazitaxel operates by inhibiting microtubule depolymerization, thereby disrupting cancer cell division and inducing cell death.
Benefits
Cabazitaxel has demonstrated a survival benefit in mCRPC patients who have progressed after docetaxel therapy, offering an alternative treatment option when other therapies are ineffective. Its efficacy in overcoming resistance mechanisms to first-line taxanes makes it a valuable component in second-line chemotherapy regimens.
Conclusion
Cabazitaxel is a second-generation taxane that provides a therapeutic option for patients with advanced prostate cancer unresponsive to initial treatments. Its role in extending survival underscores its significance in the oncological treatment landscape. However, its use requires careful monitoring due to potential side effects, including neutropenia and gastrointestinal disturbances.
Previous
Monomethyl Auristatin E丨CAS 474645-27-7
Next